A detailed history of Janus Henderson Group PLC transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Janus Henderson Group PLC holds 11,100 shares of MLTX stock, worth $579,087. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,100
Previous 11,100 -0.0%
Holding current value
$579,087
Previous $488,000 14.55%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$38.43 - $48.6 $7,186 - $9,088
-187 Reduced 1.66%
11,100 $488,000
Q1 2024

May 15, 2024

BUY
$43.78 - $63.86 $2,845 - $4,150
65 Added 0.58%
11,287 $566,000
Q4 2023

Feb 14, 2024

SELL
$36.35 - $63.02 $3,998 - $6,932
-110 Reduced 0.97%
11,222 $677,000
Q3 2023

Nov 14, 2023

BUY
$48.35 - $61.26 $547,902 - $694,198
11,332 New
11,332 $645,000

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.93B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.